Seven of eight early participants needed at least half as much glucose through a vein. Results are expected mid-December.
Rezolute, Inc. (RZLT) announced the completion of enrollment in its Phase 3 upLIFT study for ersodetug, a treatment for tumor hyperinsulinism. Topline results are expected mid-December 2026. Earlier data showed 7 of 8 initial participants met the primary endpoint, reducing IV glucose needs by 50%. The company plans to continue its expanded access program for compassionate use.
How this was made
The 30-second read
Why it matters
The enrollment completion removes a key development hurdle and sets a clear timeline for data release, which could be a catalyst for the stock.
Market read
First‑time disclosure of full Phase 3 enrollment; sets a near‑term catalyst date for investors.
What to watch
Potential regulatory delays or competition from other hyperinsulinism therapies could dampen impact.
Background
Rezolute (Nasdaq: RZLT) focuses on treating refractory hypoglycemia caused by hyperinsulinism. The upLIFT study targets tumor‑induced hyperinsulinism.
Ticker impact
Rezolute announced full enrollment of its Phase 3 upLIFT study and expects topline data in mid‑December 2026.
potential upside as investors price in positive trial expectations; downside risk if data miss expectations
Clinical‑stage biotech stocks typically rally on positive data; the lack of results yet keeps the move speculative.
Market effects
Adds momentum to the ultra‑rare disease biotech sector and may lift peer valuations.
US biotech market sees modest interest; no broader regional effect.
Limited to investors tracking rare‑disease therapeutics worldwide.
Counterpoint
If the trial data fail to meet the primary endpoint, the stock could sharply decline despite the enrollment news.
Key entities
- companyRezolute, Inc.
Late‑stage ultra‑rare disease biotech developing ersodetug.
- executiveDr. Brian Roberts
Chief Medical Officer of Rezolute, quoted on trial progress.
